Type 2 Diabetes

SmithKline Beecham Defends its Glitazone Drug, Avandia

Published in Medical Letter on the CDC and FDA, June 11th, 2000

SmithKline Beecham issued the following statement related to glitazones and its anti-diabetes drug, Avandia (rosiglitazone maleate). This statement is based on comments made by David Wheadon, MD, director of Regulatory Affairs - North America, at the U.S. Food and Drug Administration (FDA) Endocrinology and Metabolic Advisory Committee meeting:

[helv] SmithKline Beecham fully supports the Food and Drug Administration's position that the newer thiazolidinediones, more commonly known as glitazones, including Avandia, are valuable alternatives for patients with type 2 diabetes.

Almost one year ago, the Committee reviewed the comprehensive efficacy and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2000-06-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry